First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction.

Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...

Recently published models predict that by 2035, more than 40,000 valve-in-valve procedures will be performed annually in the U.S., representing more than 15% of all TAVR procedures. 2 Future planned ...

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCuttm - the world's first ...

Sue Dumbauld's job was straining her heart. After losing weight, improving her cholesterol, she was in great shape for ...

system demonstrates favourable clinical outcomes and valve performance at 30 days in patients with severe bicuspid aortic valve (BAV) stenosis. Severe BAV stenosis presents a unique challenge for TAVI ...

Valve‐in‐valve transcatheter aortic valve replacement (TAVR ... Conversely, the younger group had a higher body mass index and a more frequent occurrence of bicuspid aortic valves.